Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

FTSE 100 closes lower on weak oil majors; Midcaps boosted by G4S

Published 14/09/2020, 08:22
Updated 14/09/2020, 18:56
© Reuters. FILE PHOTO: The London Stock Exchange Group offices are seen in the City of London, Britain

By Shashank Nayar and Ambar Warrick

(Reuters) - London's blue-chip index fell on Monday as the prospect of waning demand weighed on heavyweight energy stocks, while security firm G4S (CSE:G4S) propped up the midcap index after it rejected a takeover from Canadia's GardaWorld.

The blue-chip FTSE 100 (FTSE) shed 0.1%, with oil and gas major BP (L:BP) weighing the most after it forecast declining fossil fuel demand due to climate policies and the coronavirus epidemic. Oil prices were steady. [O/R]

The mid-cap index (FTMC) added 0.7%, with G4S (L:GFS) surging to a near seven-month high after it rejected a 2.95 billion pound ($3.8 billion) offer from Canadian security firm GardaWorld, saying it was "highly opportunistic".

Divorce talks between the United Kingdom and the European Union continued to be at the forefront, with the bloc ramping up pressure on Prime Minister Boris Johnson to step back from breaking the Brexit divorce treaty.

"Brexit is back with a bang, and there’s a growing risk that the transition period will end with no trade agreement in place between the UK and the EU," ING economists wrote in a note.

Markets are also awaiting Thursday's Bank of England policy meeting, where it is likely to signal more stimulus to lift the economy out of a deep recession that could be exacerbated by a messy Brexit.

While steady stimulus has helped the FTSE 100 bounce from its coronavirus lows earlier this year, surging cases and middling economic data have seen the index stall in recent months, with new Brexit fears also expected to weigh in the near-term.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Drugmaker AstraZeneca (L:AZN) fell slightly, despite resuming British clinical trials of its COVID-19 vaccine, which is one of the most advanced in development.

British recruiting firm SThree Plc (L:STEMS) rose 1.4% as it said its underlying sequential performance had been improving since the first half of the year.

Latest comments

yeah bs like always , who gonna take that warp speed vaccine not me !
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.